Xencor (XNCR) Current Deferred Revenue (2013 - 2024)
Xencor (XNCR) reported Current Deferred Revenue of $36.5 million for Q2 2024, up 361.67% year-over-year from $7.9 million in Q3 2023, and up 6.99% quarter-over-quarter from $34.1 million in Q1 2024.
Xencor (XNCR) Current Deferred Revenue (2013 - 2024) Analysis & Trends
Xencor (XNCR) has 12 years of Current Deferred Revenue data on file, last reported at $36.5 million in Q2 2024.
- Current Deferred Revenue for Q2 2024 came in at $36.5 million, up 361.67% year-over-year; the trailing twelve-month figure through Jun 2024 was $36.5 million (up 361.67% YoY), and the FY2022 annual result was $30.3 million, down 18.77% from the prior year.
- Current Deferred Revenue climbed to $36.5 million in Q2 2024 per XNCR's latest filing, from $34.1 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $92.6 million in Q4 2020 and troughed at $7.9 million in Q2 2023.
- A 5-year average of $37.0 million and a median of $35.3 million in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue sank 77.62% in 2023, then surged 361.67% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $92.6 million in 2020, then slumped by 59.73% to $37.3 million in 2021, then slipped by 18.77% to $30.3 million in 2022, then plunged by 69.56% to $9.2 million in 2023, then jumped by 295.49% to $36.5 million in 2024.
- Business Quant data shows XNCR's Current Deferred Revenue at $36.5 million in Q2 2024, $34.1 million in Q1 2024, and $9.2 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 36.47 Mn |
| Mar 31, 2024 | 34.09 Mn |
| Sep 30, 2023 | 9.22 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 30.10 Mn |
| Dec 31, 2022 | 30.30 Mn |
| Sep 30, 2022 | 35.20 Mn |
| Jun 30, 2022 | 35.30 Mn |
| Mar 31, 2022 | 35.50 Mn |
| Dec 31, 2021 | 37.30 Mn |
| Sep 30, 2021 | 13.00 Mn |
| Jun 30, 2021 | 19.20 Mn |
| Mar 31, 2021 | 77.80 Mn |
| Dec 31, 2020 | 92.62 Mn |
| Sep 30, 2020 | 43.80 Mn |
| Jun 30, 2020 | 44.70 Mn |
| Mar 31, 2020 | 46.20 Mn |
| Dec 31, 2019 | 45.21 Mn |
| Sep 30, 2019 | 48.20 Mn |
| Jun 30, 2019 | 45.50 Mn |